GlassScriptPhysician profile
Ron M Aryel
NPI 1235399767
$437.25
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $179.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $83.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.95 | 2020 | |
| Glaxosmithkline, LLC. | $52.36 | 2019 | |
| Eisai INC. | $48.41 | 2020 | |
| Aquestive Therapeutics, INC. | $38.88 | 2019-2020 | |
| Sanofi Pasteur INC. | $34.34 | 2019 | |
| Sk Life Science, INC. | $28.35 | 2020 | |
| Neurelis, INC. | $23.15 | 2020 | |
| Genzyme Corporation | $22.81 | 2019 | |
| Upsher-Smith Laboratories LLC | $21.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Aryel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.